Human Papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes - correlation with clinico-pathological parameters and prognostic significance

Abstract

The detection of HPV 16 genotype may play an important adjunct role in assessing prognosis of cervical cancer patients. The clinical impact of the presence of HPV DNA in primary tumors and cancer free pelvic lymph nodes remains to be investigated in further studies. The exact mechanisms by which HPV influence the prognosis of cervical cancer patients have to be defined.

Clinical Effect of Human Papillomavirus Genotypes in Patients With Cervical Cancer Undergoing Primary Radiotherapy

“…In accordance with the results from other groups, patients with HPV-negative tumors tended to have a worse survival rate (9,18,(21)(22)(23), although a contradictory result was suggested by Pilch et al (20). Recently, HPV infection has also been associated with improved outcomes in patients with squamous cell carcinoma of the head and neck, especially of the oropharynx (24).…”

Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections

“…The clinical impact of high-risk HPV, particularly HPV-16 and HPV-18 has been evaluated in different studies (Lai et al, 2007;Schwartz et al, 2001;Pilch et al, 2001) and these strains are associated with poor prognosis in cervical cancer patients, poor overall survival and cancer relapse. In one study 20 percent of women with the highest HPV 16 quantities had a 60-fold increased risk of carcinoma in situ of the cervix compared to HPV negative controls (Josefsson et al, 2000).…”

Comparison of the PapilloCheck® DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set

“…[6][7][8] Trials are on-going to determine the most effective algorithm for detection of high-grade cervical intraepithelial neoplasia (CIN2+) in primary screening. 9,10 HPV 16 and 18 are linked to worse prognosis, poor survival rates and relapse in cervical cancer patients [11][12][13] and studies show testing for oncogenic HPV is a sensitive, costeffective measure in follow up of women treated for CIN and in triage of women with borderline and mild dyskaryosis. [14][15][16][17] Against this background, introduction of HPV testing appears likely, however a number of issues remain to be resolved, including which HPV test to use, whether HPV will be used as a primary screen or triage test, and how best to manage positive results.…”